PDS Biotechnology Corporation (NASDAQ:PDSB) does about 920.27K shares in volume on a normal day but saw 932434 shares change hands in Tuesday trading. The company now has a market cap of 119.94M USD. Its current market price is $3.27, marking a decrease of -1.21% compared to the previous close of $3.31. The 52 week high reached by this stock is $10.27 whilst the lowest price level in 52 weeks is $3.14.
PDS Biotechnology Corporation (PDSB) has a 20-day trading average at $4.22 and the current price is -68.16% off the 52-week high compared with 4.14% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.04 and its 200-day simple moving average is $5.14. If we look at the stock’s price movements over the week, volatility stands at 8.39%, which increases to 8.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 28.00 to suggest the stock is oversold.
The consensus objective for the share price is $14.40, suggesting that the stock has a potential upside of 77.29% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 01, 2022 when B. Riley Securities initiated the stock to “Buy” and issued a price target of $10. H.C. Wainwright upgraded its price target at $6.
PDS Biotechnology Corporation (PDSB) stock is down -12.10% over the week and -40.11% over the past month. Its price is -34.21% year-to-date and -43.72% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.35 above consensus estimates by $0.09. PDSB’s earnings per share are forecast to shrink by -6.50% this year and -8.80% over next year.
To reach the target analysts have set, the stock logically needs to grow 77.29 percent from here.
Outstanding shares total 36.68M with insiders holding 4.33% of the shares and institutional holders owning 27.03% of the company’s common stock. The company has a return on investment of -93.84% and return on equity of -122.46%. The beta has a value of 1.74. Price to book ratio is 4.14.
